- Home
- TDUP vs ATXS Comparison
TDUP vs ATXS Comparison
Compare TDUP & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- ATXS
- Stock Information
- Founded
- TDUP 2009
- ATXS 2008
- Country
- TDUP United States
- ATXS United States
- Employees
- TDUP N/A
- ATXS N/A
- Industry
- TDUP Catalog/Specialty Distribution
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- ATXS Health Care
- Exchange
- TDUP Nasdaq
- ATXS Nasdaq
- Market Cap
- TDUP 368.3M
- ATXS 401.2M
- IPO Year
- TDUP 2021
- ATXS 2015
- Fundamental
- Price
- TDUP $3.32
- ATXS $4.04
- Analyst Decision
- TDUP Buy
- ATXS Strong Buy
- Analyst Count
- TDUP 5
- ATXS 5
- Target Price
- TDUP $3.50
- ATXS $26.60
- AVG Volume (30 Days)
- TDUP 1.1M
- ATXS 365.8K
- Earning Date
- TDUP 05-05-2025
- ATXS 05-08-2025
- Dividend Yield
- TDUP N/A
- ATXS N/A
- EPS Growth
- TDUP N/A
- ATXS N/A
- EPS
- TDUP N/A
- ATXS N/A
- Revenue
- TDUP $260,031,000.00
- ATXS N/A
- Revenue This Year
- TDUP $8.43
- ATXS N/A
- Revenue Next Year
- TDUP $6.58
- ATXS N/A
- P/E Ratio
- TDUP N/A
- ATXS N/A
- Revenue Growth
- TDUP 0.59
- ATXS N/A
- 52 Week Low
- TDUP $0.50
- ATXS $3.56
- 52 Week High
- TDUP $3.54
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- TDUP 66.68
- ATXS 28.96
- Support Level
- TDUP $3.16
- ATXS $3.56
- Resistance Level
- TDUP $3.54
- ATXS $4.39
- Average True Range (ATR)
- TDUP 0.24
- ATXS 0.42
- MACD
- TDUP 0.06
- ATXS -0.04
- Stochastic Oscillator
- TDUP 82.80
- ATXS 22.61
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.